Aprea Therapeutics, Inc. APRE
0.76
(0.02)
(2.56%)
as of 25 Sep
- Market cap
- $9.8M
- P/E
- 0.0×
Follow APRE
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 0.00 | 12.06 | 19.45 |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | — | (4.84) | (5.16) | (1.88) |
P/B ratio |
— | — | — | — | — | — | 1.07 | 0.94 | 0.45 |
Price to Tangible BV |
— | — | — | — | — | — | 1.07 | 0.94 | 0.45 |
EV/Sales |
— | — | — | — | — | — | 0.00 | (3.14) | (31.65) |
EV/EBITDA |
— | — | — | — | — | — | 0.23 | 0.33 | 0.68 |
EV/Operating CF |
— | — | — | — | — | — | 0.29 | 0.35 | 0.70 |
EV/FCF |
— | — | — | — | — | — | 0.29 | 0.35 | 0.70 |
Quick Ratio |
— | 13.49 | 14.36 | 5.81 | 7.25 | 8.99 | 4.93 | 6.80 | 5.28 |
Current Ratio |
— | 13.56 | 14.68 | 6.03 | 7.73 | 9.42 | 5.14 | 7.01 | 5.63 |
Net Debt/EBITDA |
0.00 | 3.98 | 4.43 | 1.69 | 1.43 | 0.25 | 1.40 | 1.60 | 1.11 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.06 | 0.01 |
Operating CF/Net income |
0.92 | 0.98 | 0.95 | 0.78 | 1.02 | 0.22 | 0.85 | 1.05 | 1.02 |
Capex/Depreciation |
0.00 | (0.45) | (0.18) | (0.11) | 0.00 | 0.00 | (13.11) | (0.70) | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | (42.66%) | (77.08%) | (53.04%) | (58.51%) | (299.83%) | (67.08%) | (71.47%) | (79.37%) | |
| (46.02%) | (47.04%) | (28.11%) | (47.24%) | (49.63%) | (259.05%) | (54.11%) | (55.58%) | (63.14%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
0.00% | (25.39%) | (22.62%) | (69.34%) | (75.32%) | (417.97%) | (78.40%) | (63.85%) | (98.00%) |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,307.87% | 623.15% | 2,464.31% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,445.08% | 429.83% | 2,266.13% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 76.22% | 32.57% | 167.28% |
Graham Net Nets |
— | — | — | — | — | — | 0.93 | 1.04 | 2.17 |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (79.80%) | (72.34%) | (232.94%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (67.93%) | (74.87%) | (232.27%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.27 | 0.04 |
Operating CF per Share |
(242.67) | (264.30) | (89.00) | (39.55) | (35.41) | (15.09) | (3.37) | (2.46) | (1.97) |
Capex per Share |
0.00 | (0.06) | (0.10) | (0.02) | 0.00 | 0.00 | (0.03) | 0.00 | 0.00 |
Free Cash Flow per Share |
(242.67) | (264.37) | (89.10) | (39.57) | (35.41) | (15.09) | (3.39) | (2.46) | (1.97) |
Cash per Share |
0.00 | 1,138.23 | 433.49 | 84.22 | 49.87 | 17.37 | 5.97 | 4.15 | 2.23 |
Shareholders Equity per Share |
0.00 | 1,059.87 | 414.01 | 73.22 | 46.52 | 15.48 | 4.69 | 3.50 | 1.90 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 1,059.87 | 414.01 | 73.22 | 46.52 | 15.48 | 4.69 | 3.50 | 1.90 |
Free Cash Flow |
(14.00) | (15.25) | (26.74) | (41.83) | (37.69) | (25.01) | (12.27) | (13.57) | (12.89) |
Working Capital |
— | 61.13 | 123.98 | 77.09 | 49.27 | 26.95 | 18.14 | 20.22 | 12.80 |
Capital Expenditures |
— | 0.00 | (0.03) | (0.03) | — | — | (0.09) | (0.02) | — |
Net Current Asset Value |
0.00 | 61.13 | 123.68 | 77.01 | 49.27 | 25.64 | 16.82 | 18.90 | 12.07 |
EV/EBIT |
— | — | — | — | — | — | 0.23 | 0.33 | 0.68 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | — | — | 0.16 | 0.01 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (2,449.73%) | (862.42%) | (4,408.54%) |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.00 | 0.34 | 4.09 | 5.96 | 11.37 | 81.04 | 0.08 | 0.27 | 0.36 |
Cash ROIC |
0.00% | (12.04%) | (10.52%) | (25.14%) | (36.76%) | (45.95%) | (31.81%) | (32.35%) | (47.91%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 1.96 | 1.96 | 3.34 | 3.14 | 1.31 | 1.26 | 1.51 | 1.03 |
Average Assets |
33.01 | 33.01 | 99.82 | 113.21 | 74.81 | 43.49 | 26.40 | 23.31 | 19.96 |
Average Common Equity |
— | 36.40 | 36.40 | 100.82 | 63.45 | 37.58 | 21.30 | 18.13 | 15.87 |
Columns are period end dates